BiotechTube

protein subunit: Novavax COVID-19 vaccine + Pfizer mRNA COVID-19 vaccine

ApprovedActive
0 watching 0 views this week🔥 Hot
80
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

COVID-19

Conditions

COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection

Trial Timeline

Sep 20, 2024 → Aug 31, 2025

NCT ID
NCT06633835

About protein subunit: Novavax COVID-19 vaccine + Pfizer mRNA COVID-19 vaccine

protein subunit: Novavax COVID-19 vaccine + Pfizer mRNA COVID-19 vaccine is a approved stage product being developed by Novavax for COVID-19. The current trial status is active. This product is registered under clinical trial identifier NCT06633835. Target conditions include COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection.

Hype Score Breakdown

Clinical
30
Activity
20
Company
5
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT06633835ApprovedActive

Competing Products

20 competing products in COVID-19

See all competitors
ProductCompanyStageHype Score
Human COVID-19 immunoglobulin (pH4) for intravenous injection + PlaceboSinopharmPhase 2
51
Mavrilimumab + PlacebosKiniksa PharmaceuticalsPhase 2
47
Gimsilumab + PlaceboRoivant SciencesPhase 2
49
Icosapent ethylAmarin CorporationPhase 2
44
Bamlanivimab + Placebo + EtesevimabEli LillyPhase 3
77
InfliximabCelltrionPhase 2
52
CT-P63 and CT-P66 / PlaceboCelltrionPhase 3
77
Enzalutamide PillAstellas PharmaPhase 2
52
S-892216 + PlaceboShionogiPhase 2
52
S-892216 + CarbamazepineShionogiPhase 1
33
FOY-305 + PlaceboOno PharmaceuticalPhase 3
77
DesidustatZydus LifesciencesPhase 2
52
LY3819253 + PlaceboEli LillyPhase 1
33
Bamlanivimab + Etesevimab + Placebo + VIR-7831 + BebtelovimabEli LillyPhase 2
52
BamlanivimabEli LillyPhase 2
52
LY3127804 + PlaceboEli LillyPhase 2
52
Baricitinib + PlaceboEli LillyPhase 3
77
BamlanivimabEli LillyPre-clinical
23
LY3819253 + Placebo + RemdesivirEli LillyPhase 3
77
LY3819253 + LY3832479 + LY3853113 + PlaceboEli LillyPhase 2/3
65

Other Products from Novavax

Novavax COVID-19 vaccine (2023-2024 formula XBB containing) + Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)Approved
80
NVX-CoV2705 + PlaceboApproved
80
NVX-CoV2373 + BBIBP-CorV vaccinePhase 3
72
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period) + SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period) + SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination) + SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)Phase 3
72
RSV-F Vaccine + Phosphate Buffer PlaceboPhase 3
72